Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...
Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, Arcus Biosciences ... It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
Bionomics Limited (Nasdaq: BNOX), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, made waves in the stock market this week.
Bionomics shares are trading higher by 104% Tuesday morning. The company announced a AUD$1 million milestone payment from ...
Summit Therapeutics may have a powerful new cancer therapy on its hands. Merck is milking its cash cow oncology drug ... In ...
(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...
Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...
Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.
Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...